SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
nSEPIA aims to bring structure to an area long dominated by subjectivity
AI-powered platform uses real-time emotion scanning and personalised interventions to make emotional wellness measurable and actionable
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Highlights Mirvetuximab-based regimen promise
Routine regulatory filing confirms completion of demat and share transfer compliances for March quarter
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
Subscribe To Our Newsletter & Stay Updated
